Korean Guideline for Iron Chelation Therapy in Transfusion-Induced Iron Overload
Journal of Korean Medical Science
;
: 1563-1572, 2013.
Artículo
en Inglés
| WPRIM
| ID: wpr-221307
ABSTRACT
Many Korean patients with transfusion-induced iron overload experience serious clinical sequelae, including organ damage, and require lifelong chelation therapy. However, due to a lack of compliance and/or unavailability of an appropriate chelator, most patients have not been treated effectively. Deferasirox (DFX), a once-daily oral iron chelator for both adult and pediatric patients with transfusion-induced iron overload, is now available in Korea. The effectiveness of deferasirox in reducing or maintaining body iron has been demonstrated in many studies of patients with a variety of transfusion-induced anemias such as myelodysplastic syndromes, aplastic anemia, and other chronic anemias. The recommended initial daily dose of DFX is 20 mg/kg body weight, taken on an empty stomach at least 30 min before food and serum ferritin levels should be maintained below 1000 ng/mL. To optimize the management of transfusion-induced iron overload, the Korean Society of Hematology Aplastic Anemia Working Party (KSHAAWP) reviewed the general consensus on iron overload and the Korean data on the clinical benefits of iron chelation therapy, and developed a Korean guideline for the treatment of iron overload.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Piridonas
/
Triazoles
/
Benzoatos
/
Transfusión Sanguínea
/
Síndromes Mielodisplásicos
/
Terapia por Quelación
/
Quelantes del Hierro
/
Sobrecarga de Hierro
/
República de Corea
/
Anemia Aplásica
Tipo de estudio:
Guía de Práctica Clínica
Límite:
Humanos
País/Región como asunto:
Asia
Idioma:
Inglés
Revista:
Journal of Korean Medical Science
Año:
2013
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS